Bangladesh has launched a major initiative to locally produce dengue, rabies and measles vaccines, along with snakebite antivenom, in a bid to reduce dependence on imported lifesaving medicines and strengthen public healthcare resilience.
State-owned Essential Drugs Company Limited (EDCL) is leading the project, which officials say is designed to meet urgent domestic demand while laying the groundwork for long-term self-sufficiency in critical biologics. Health authorities also hope the initiative will eventually position Bangladesh as a regional supplier of vaccines and antivenom.
The move comes as the country continues to face repeated public health emergencies. Dengue outbreaks have intensified in recent years, measles infections have resurfaced due to immunisation gaps, and hospitals frequently report shortages of rabies vaccines and snakebite treatment.
Health officials said dengue alone caused 413 deaths and more than 100,000 infections in 2025. Measles cases have also risen sharply this year, with nearly 40,000 infections and over 320 child deaths reported nationwide.
Snakebite remains a major but underreported crisis. A national survey estimates around 400,000 snakebite cases annually, leading to more than 7,500 deaths each year, many of which are preventable with timely access to antivenom. Despite this burden, Bangladesh currently has no domestic antivenom production facility and depends heavily on imports.
EDCL Managing Director Md A Samad Mridha said the initiative was taken under government direction in response to rising health risks. "Dengue, rabies, snakebite and measles have become major concerns. Local production is now essential," he said.
According to EDCL, production of all four products is expected to begin within a year, with supply to government hospitals targeted from June next year. The project will initially use existing infrastructure and require an estimated investment of Tk 20-25 crore.
Once operational, the facility is expected to produce 9-10 million vials annually, against a national demand of about 5 million doses. Officials said this could eventually allow surplus production for export.
Experts say the biggest benefit will be reduced costs and improved supply stability. Locally produced vaccines could cost nearly half of imported equivalents, saving significant foreign exchange while reducing shortages during outbreaks.
EDCL also plans to manufacture Qdenga, a dengue vaccine developed by Takeda, which received World Health Organization prequalification in 2024 for children in high-risk regions.
Alongside this, a larger vaccine, therapeutic and diagnostic research centre is being developed in Sirajdikhan, Munshiganj, on 10 acres of land with Asian Development Bank financing. Production there is expected to begin by 2032.
Health policy analysts say the combined initiatives could transform Bangladesh's pharmaceutical sector, but stress that success will depend on maintaining international quality standards, ensuring technology transfer and developing skilled manpower for biologics manufacturing.
